You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | -2,807.5% | -1,636.1% |
| ROCE | 0.0% |
| Latest | Forecast | |
|---|---|---|
| P/E | -1.5 | 0.0 |
| PEG | 0.0 | -999,999.0 |
| Price / Revenue | 37.1 | 22.0 |
| Price / Book value | 1.5 |
| Latest | Forecast | |
|---|---|---|
| Revenue | 53.8% | 21.1% |
| PBT | 0.0% | n/a |
| EPS | 0.0% | -28.7% |
| DPS | n/a | 0.0% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2018-03-31 | 0.04 | -20.97 | -54.23p | -1.5 | 0.0 | n/a | n/a | 0.0% |
| 2019-03-31 | 0.05 | -17.23 | -44.11p | -2.3 | 0.0 | n/a | n/a | 0.0% |
| 2020-03-31 | 6.07 | -13.86 | -34.96p | -2.8 | 0.0 | n/a | n/a | 0.0% |
| 2021-03-31 | 0.26 | -13.41 | -29.00p | -4.1 | 0.0 | n/a | n/a | 0.0% |
| 2022-03-31 | 0.40 | -11.06 | -17.00p | -1.8 | 0.0 | n/a | n/a | 0.0% |
| ReNeuron enters cancer therapy collaboration with UCL Sharecast News | 26 Oct |
|---|---|
| Director dealings: Reneuron Group non-executive makes share purchase Sharecast News | 21 Oct |
| ReNeuron treats first Oxford patient as part of expanded study Sharecast News | 18 Oct |
| Directorate Change | 01-Aug-22 07:00 |
|---|---|
| Grant of Options | 15-Jul-22 07:00 |
| Share Purchase by a Director | 14-Jul-22 07:00 |
| Share Purchase by a Director | 13-Jul-22 07:00 |
| Preliminary Results | 04-Jul-22 07:00 |